Alnylam Pharmaceuticals
ALNY
#1135
Rank
NZ$36.18 B
Marketcap
NZ$270.19
Share price
-0.58%
Change (1 day)
-66.92%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$35.04

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$36.03. In 2025 the company made an earnings per share (EPS) of NZ$3.20.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$35.04994.59%
2025NZ$3.20
2023NZ-$6.42-62%
2022NZ-$16.9029.03%
2021NZ-$13.10-3.36%
2020NZ-$13.55-8.48%
2019NZ-$14.817.67%
2018NZ-$13.7539.74%
2017NZ-$9.8412.94%
2016NZ-$8.7138.84%
2015NZ-$6.28-32.88%
2014NZ-$9.35259.44%
2013NZ-$2.60-31.25%
2012NZ-$3.78

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$9.55-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.60-90.00%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$85.46 137.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.78-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.33-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.35-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$0.82-97.73%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ-$6.06-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA